Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01901341CT.gov The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | — | Terminated | — | — | — |
NCT01901302CT.gov Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | — | Terminated | — | — | — |
NCT01901328CT.gov Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | — | Terminated | — | — | — |
NCT01696643CT.gov Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | — | Terminated | — | — | — |
NCT01207427CT.gov Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Opioid-Induced Constipation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bevenopran (this asset) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | P3 | CCC · 50 |
| Naldemedine | BioDelivery Sciences International | P3 | BBB |
| Methylnaltrexone | Bausch Health Americas, Inc. | P3 | B |
| Prucalopride | Shire | P3 | B |
| Rdc-1036 | Alkermes, Inc. | P2 | B |
| Morphinan-3,6,14-Triol, 4,5-Epoxy-17-(2-Propenyl)-, (5.Alpha.,6.Beta.)- | S.L.A. Pharma AG | P2 | B |
| Lactobacillus Gasseri Bgp345A | BioGaia Pharma AB | P2 | B |
| Linaclotide | Forest Laboratories | P2 | B |
| Naloxegol | BioDelivery Sciences International | Unk | D |
+2 more in the Opioid-Induced Constipation cohort
Other indications for Bevenopran
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Constipation Disorder | — | P2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bevenopran in Opioid-Induced Constipation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bevenopran-opioid-induced-constipation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →